Redeye concludes SSH Communications Q1’23 was weaker than expected due to customers’ hesitance to pl...
Redeye comments on the Q1 report released earlier this morning.
Solid Q1, in line with consensus Strategic case remains unchanged after recent CMD No estimate chang...
Solid start to 2023, but weakness in some industries We lower '23e-'25e sales by 2-1% 14% adj.
Redeye thinks the change of CFO appears to be a change of co-pilot from the CEO, rather than Martin ...
Atria reported strong headline figures for Q1, clearly beating Refinitiv consensus expectations desp...
Agilyx published its 2022 results on 25 April, with the report highlighting significant demand momen...
Redeye argues that the Q1 operational update from Zwipe was weaker than we expected.
ChargePanel AB (publ) meddelade den 24 april att bolaget har ingått ett avtal för både ChargePanel E...
Redeye reiterates its SEK173 base case following today’s announced Framework agreement with NHS and ...
CirChem har vunnit en upphandling och tecknat ramavtal med Gryaab för leverans av lösningsmedel.
Redeye notes that Acuvi’s preliminary Q1 numbers are rather sluggish in terms of sales.
Högre omsättning stärker marginalen CAG rapporterade under morgonen sin Q1-rapport.
Bra orderingång Verksamhetsuppdateringen för Q1 2023 visade att tillväxten håller i sig trots ett bi...
Redeye provides a research update on Lipum following the Q1 report published by the company earlier ...
Redeye saw results that did not represent a significant deviation from the expectations.
Loihde reports its Q1 results on Friday, April 28th.
Innofactor’s Q1 results were good and surpassed our expectations.
Redeye embraces Devyser’s agreement with Thermo Fisher regarding its post-transplantation monitoring...
Adj. EBIT SEK 2.7m (ABGSCe 5.9m) Q1 numbers imply ~1% negative adj.
